GlassScriptPhysician profile
Ian S Alward
NPI 1790764058
$12,411.41
in general payments reported to CMS, 2019-2025
50 companies · $93.26 in 2025
The $93.26 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,558 · 2020: $2,272 · 2021: $2,398 · 2022: $2,751 · 2023: $2,297 · 2024: $42.82 · 2025: $93.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,433.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,432.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,419.88 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $1,128.97 | 2019-2023 | Ozempic, Rybelsus |
| Lilly USA, LLC | $932.49 | 2019-2025 | Zepbound, Jardiance, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $925.62 | 2019-2023 | Jardiance, Synjardy |
| Astrazeneca Pharmaceuticals LP | $904.34 | 2019-2023 | Breztri |
| Abbvie INC. | $705.32 | 2019-2023 | Vraylar, Ubrelvy, Qulipta |
| Gilead Sciences, INC. | $553.39 | 2019-2023 | |
| Jazz Pharmaceuticals INC. | $512.05 | 2021-2023 | Rylaze |
| Sanofi-Aventis U.S. LLC | $504.61 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $464.57 | 2019-2023 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $447.06 | 2019-2023 | Trintellix |
| Pfizer INC. | $379.92 | 2019-2023 | |
| Allergan, INC. | $322.97 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $292.06 | 2022-2023 | |
| Amgen INC. | $286.04 | 2019-2022 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ian Alward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.